

1 **Causal association between serum bilirubin and ischemic stroke:**
2 **Multivariable Mendelian Randomization**

3
4 Jong Won Shin^{1)*}, Keum Ji Jung^{1,2)*}, Heejin Kimm^{1,2)}, Sun Ha Jee^{1,2)}

5 1) Department of Epidemiology and Health Promotion, Graduate School of
6 Public Health, Yonsei University, Seoul, Korea

7 2) Institute for Health Promotion, Department of Epidemiology and Health
8 Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea

9
10 * Both authors contributed equally as first authors.

11
12 Running title: Serum bilirubin and ischemic stroke

13
14 **Correspondence:**

15 Sun Ha Jee, PhD, MPH

16 Department of Epidemiology and Health Promotion, Graduate School of
17 Public Health,

18 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03772, Korea

19 Tel: 82-2-2228-1523, E-mail: jsunha@yuhs.ac

25 **Abstract (230)**

26 **BACKGROUND:** Past studies have mainly focused on total bilirubin levels, and have
27 not clearly distinguished between direct and indirect bilirubin, a subgroup of bilirubin.
28 In this study, the differences between these subgroups were clearly examined, and
29 the causal association with ischemic stroke was examined in more detail.

30 **METHODS:** Utilizing Two sample Multivariable Mendelian randomization (MVMR)
31 analyses, summary data for bilirubin were extracted from the KCPS-II (Korean
32 Cancer Prevention Study-II; n=159,844) and the KoGES (Korean Genome and
33 Epidemiology Study; n=72,299), while ischemic stroke data were derived from the
34 BBJ (Bio Bank Japan; n=201,800).

35 **RESULTS:** The crude two-sample MR analysis revealed a significant negative
36 association between total bilirubin and ischemic stroke in KoGES data (odds ratio
37 [OR], 0.86; 95% confidence interval [CI], 0.75-0.98). Subsequent bivariable MR
38 analyses, controlling for lipid profile, also showed significant results. In KCPS-II data,
39 direct bilirubin showed significance in both crude (0.65, 0.43-0.97) and bivariable
40 analyses, while indirect bilirubin demonstrated significant associations in MVMR
41 analyses (0.76, 0.59-0.98), emphasizing its role in mitigating the risk of ischemic
42 stroke.

43 **CONCLUSIONS:** Our study establishes a causal association between genetically
44 determined levels of serum bilirubin (total, direct, and indirect) and a reduced risk of
45 ischemic stroke in an Asian population. Notably, the protective effect was
46 predominantly associated with indirect bilirubin. The findings highlight the
47 significance of considering bilirubin subgroup in understanding the mechanisms
48 underlying endogenous antioxidants and its impact on ischemic stroke.

49 **Key Words:** bilirubin, ischemic stroke, multivariable mendelian randomization

50 INTRODUCTION

51

52 Stroke is a form of oxidative stress-related disease.^{1,2,3} Serum bilirubin levels are
53 widely reported to be inversely related to stroke risk in both Western populations^{4,5}
54 and Asian populations.^{6,7} These studies have been based on serum total bilirubin
55 levels. In other words, it is a result that does not take into account the specific levels
56 of direct bilirubin (conjugated bilirubin) and indirect bilirubin (unconjugated bilirubin)
57 that make up the total bilirubin. In fact, indirect bilirubin levels account for a large
58 proportion of the subgroups of total bilirubin (reference values - total bilirubin: 0.3-1.0
59 mg/dl, direct bilirubin: 0-0.3 mg/dl, indirect bilirubin: 0.2-0.8 mg/dl). Aged red blood
60 cells are broken down into heme and globin, and then heme is broken down into iron
61 (Fe²⁺) and biliverdin. In the process of oxidation to biliverdin (Figure 1), the level of
62 indirect bilirubin acts as a powerful endogenous antioxidant.^{8,9}

63 The First study on total bilirubin and stroke occurrence using genetic information was
64 a case-cohort design of 806 stroke patients that occurred in a subcohort of 4,793
65 subjects in the KCPS-II (Korean Cancer Prevention Study-II). This study, a one-
66 sample mendelian randomization (MR) analysis, showed a negative association
67 between total bilirubin and total stroke (HR=0.63, 95% CI 0.30–1.36), but did not
68 show statistically significant results (p=0.240).¹⁰ The second study performed a two-
69 sample MR analysis of total bilirubin based on KoGES (Korean Genome and
70 Epidemiology Study; n=25,406) and KCPS-II (n=14,541) biobank data.¹⁰ The results
71 provided evidence for a significant causal association between total bilirubin levels
72 and reduced risk of stroke in the Korean population. In particular, the association
73 was greater for ischemic stroke (OR=0.302) than for total stroke (OR=0.481).¹¹

74 However, considering only serum total bilirubin, there was insufficient specific
75 evidence to suggest a reduction in stroke risk through bilirubin's role as an
76 endogenous antioxidant.

77 **OBJECTIVES**

- 78 1. We divided bilirubin into subgroups to determine whether each subgroup
79 plays a role as an endogenous antioxidant.
- 80 2. We also investigated whether it was possible to suggest the significance of
81 causal associations when adjusting for several genetic variables, which was
82 not possible in existing MR studies.

83

84 **METHODS**

85 We analyzed total, direct, and indirect bilirubin data from KoGES (n=72,299)¹² and
86 KCPS-II (n=159,844) biobanks¹³ and ischemic stroke from BBJ (BioBank Japn;
87 n=201,800).¹⁴ data was used to perform Two Sample Multivariable MR (MVMR). In
88 other words, MVMR was performed to control blood pressure, fasting blood sugar,
89 and serum lipid levels related to stroke.

90

91 ***Genetic instruments for serum bilirubin (G-X)***

92 A genetic instrumental variable for serum bilirubin was identified using two Korean
93 biobanks (KCPS-II and KoGES).^{12,13} The selection of instrumental variables for MR
94 analysis was based on the following criteria: First, cases with a *p-value* smaller than
95 the genome-wide significance level identified in the study (*p-value* <5x10⁻⁸). The
96 second, minor allele frequency (MAF) is greater than 0.01. The third, single
97 nucleotide polymorphism (SNP)s with linkage disequilibrium (LD) relationship were

98 excluded (clumping criteria: r^2 0.001 standard). Finally, palindromic (SNP) was
99 excluded from the analysis (MAF > 0.42).

100

101

102 ***Genetic associations of SNPs with ischemic stroke (G-Y)***

103 Summary data used for ischemic stroke were obtained from BBJ.¹⁴ BBJ is a biobank
104 composed of 201,800 patient data centered on 66 hospitals nationwide between
105 2003 and 2008.

106

107 ***Mendelian randomization***

108 In this study, G-X data on exposure as two-sample MR came from KCPS-II and
109 KoGES. And G-Y data for outcome came from BBJ. The coefficient was estimated
110 using the inverse variance weighted (IVW) method under the assumption that all
111 selected SNPs were valid. At this study, coefficient was calculated by calculating the
112 coefficient of each SNP according to the wald ratio method and combining it using
113 the IVW method.

114 Multivariable MR (MVMR) analysis was performed controlling for genetic variables of
115 triglyceride (TG), cholesterol (LDL; low density lipoprotein, HDL; high density
116 lipoprotein), systolic blood pressure (SBP), and fasting blood sugar (FBS), which are
117 noted as major causes of stroke. To ensure the validity of instrumental variables, the
118 F-value of each variable was presented in each model.

119

120 Analyses were conducted using the Two Sample MR package in R, version 3.6.0 (R
121 Project for Statistical Computing).

122

123 **RESULTS**

124

125 This study divided bilirubin into total, direct, and indirect bilirubin and analyzed
126 Mendelian randomization for each of them for their association with the risk of
127 ischemic stroke. In this study, summary data for bilirubin was extracted from KoGES
128 and KCPS-II, respectively, and summary data for ischemic stroke was used from
129 BBJ data.

130 Table 1 shows crude two-sample MR and MVMR results on the effect of total
131 bilirubin on ischemic stroke. It showed a significant negative association that crude
132 two sample MR analysis between total bilirubin and ischemic stroke in KoGES data
133 (OR, 0.86, 95%CI, 0.75-0.98). In addition, MVMR, controlling for LDL, HDL, and TG,
134 respectively, showed significant results. Additionally, there are borderline significant
135 results in the crude two-sample MR results and in the model controlling LDL from
136 KCPS-II. However, MVMR, controlling for HDL and TG, showed significant results. In
137 the remaining models, a negative association between total bilirubin and ischemic
138 stroke was observed, but it was not significant (Figure 1-A). The F-statistic of total
139 bilirubin and other variables used in the model in Table 1 were all above 10 except
140 for systolic blood pressure (SBP), and the assumption as an instrumental variable
141 was satisfied (Supplementary Table 1).

142 Table 2 shows the crude two sample MR and MVMR results on the effect of direct
143 bilirubin on ischemic stroke. KoGES data analysis showed a significant negative
144 association only in crude two-sample MR ($p=0.0493$). However, KCPS-II data
145 analysis showed significant results in crude two sample MR, and also showed

146 significant results in MVMR with LDL, HDL, and TG controlled respectively. The
147 remaining model showed a negative relationship, but it was not significant (Figure 1-
148 B). The F values of direct bilirubin and control variables used in the model in Table 2
149 were all above 10 except for SBP, and the assumption as an instrumental variable
150 was satisfied (Supplementary Table 2).

151 Table 3 showed the crude two sample MR and MVMR results on the effect of indirect
152 bilirubin on ischemic stroke. KoGES results showed a significant negative correlation
153 only in crude two sample MR ($P=0.0253$). However, in the KCPS-II data analysis, the
154 crude two sample MR showed a borderline significant result, but the MVMR analysis
155 controlling the remaining LDL, HDL, and TG showed a significant result. In addition,
156 MVMR, which simultaneously controlled LDL, HDL, and TG, showed significant
157 results ($P=0.0355$). This model showed significant results for indirect bilirubin even
158 when SBP or FSG was additionally controlled (right side of Figure 1-C). The F values
159 of indirect bilirubin and control variables used in the model in Table 3 were all above
160 10 except for SBP, and the assumption as an instrumental variable was satisfied
161 (Supplementary Table 3).

162 In the models presented in Tables 1, 2, and 3, the common feature of the other
163 control factors except bilirubin was that only SBP consistently showed a significant
164 causal relationship to the risk of ischemic stroke. However, LDL, TG, and FBS were
165 not significant.

166

167 **DISCUSSION**

168

169 In this study, we showed that genetically determined levels of each bilirubin (total,

170 direct, and indirect bilirubin) in serum were causally associated with reduced risk of
171 ischemic stroke in an Asian population. In particular, it was demonstrated that only
172 indirect bilirubin had a strong protective effect in MVMR, which controlled for genetic
173 factors related to ischemic stroke.

174 This study performed two sample MR to investigate the causal relationship between
175 genetically determined levels of circulating serum bilirubin (total, direct, and indirect
176 bilirubin) and the risk of ischemic stroke. In addition, the causal relationship was
177 shown while controlling for genetic variables of TG, cholesterol (HDL, LDL), SBP,
178 and FBS.

179 Interestingly, while controlling for genetic variables such as TG, cholesterol (HDL,
180 LDL), SBP, and FBS, indirect bilirubin levels reduced the risk of ischemic stroke. On
181 the other hand, for direct bilirubin, a somewhat weaker association was found. These
182 research results are expected to contribute to understanding the mechanisms
183 caused by oxidative stress in the future.

184 In the metabolic process of bilirubin, heme is broken down by heme oxygenase to
185 produce carbon monoxide (CO), iron (Fe), and biliverdin.^{15,16} In normal, healthy liver
186 cells, biliverdin is converted to bilirubin via biliverdin reductase A (BVRA). Biliverdin
187 reductase exists as two type of isoenzymes. BVRA and biliverdin reductase B
188 (BLVRB) produce bilirubin IX α and bilirubin IX β , respectively.¹⁵ BVRA is critical for
189 adult bilirubin production forming bilirubin IX α , whereas bilirubin IX β is mostly
190 present during fetal development. Bilirubin IX α is insoluble and binds to albumin in
191 the blood (indirect bilirubin, unconjugated bilirubin), where it is transported to the liver
192 and conjugated.¹⁵

193 Afterwards, bilirubin is conjugated in hepatocytes by the UGT1A1 UDP-

194 glucuronosyltransferase enzyme (direct bilirubin, conjugated bilirubin) and is
195 eventually excreted in bile and reaches the intestines.^{16,17}

196 Conjugated bilirubin is isolated by intestinal bacteria and reduced to urobilinoid. In
197 this way, the enzymes and activity sites involved in each bilirubin during the
198 metabolic process are different. Since the manifestation of the disease according to
199 the increase or decrease in each of these levels appears completely different, it is
200 believed that the classification of total bilirubin subgroups will have a significant
201 impact on the results and direction of the research.

202 In two Sample MR, exposure variables and outcome data are each extracted from
203 two independent biobanks. This is advantageous when exposure and outcome data
204 are not available from the same biobank. This study used serum bilirubin data from
205 KoGES and KCPS-II. For ischemic stroke data, MR analysis could be performed
206 using the same Asian data from BBJ.

207 Additionally, utilizing multiple samples improves the overall sample size and
208 subsequent precision of causal effect estimates. As a result, we not only re-proved
209 the causal relationship between bilirubin levels and stroke risk reduction in Korean
210 cases in the previous study,^{10,11} but also confirmed the causal relationship between
211 ischemic stroke risk reduction in Japanese as an Asian population.

212 Evidence from numerous observational studies in humans indicates a strong
213 negative association between serum bilirubin levels and cardiovascular disease. For
214 example, bilirubin has antioxidant properties, including scavenging reactive oxygen
215 species (ROS) and inhibiting nicotinamide adenine dinucleotide phosphate (NADPH)
216 oxidase activity, thereby oxidative stress, which is critically involved in the
217 pathogenesis and development of atherosclerosis.^{18,19}

218 Additionally, serum total bilirubin concentration was negatively associated with
219 arteriosclerosis in Chinese men,²⁰ and in a German population, serum bilirubin levels
220 were observed to be inversely associated with coronary artery calcification and
221 cardiovascular disease.²¹In the Chinese population, serum total bilirubin levels were
222 negatively associated with subclinical cerebral infarction, which increased the risk of
223 transient ischemic attack, symptomatic stroke, and cardiovascular disease.²²
224 Regarding stroke risk, a cross-sectional study of Americans conducted from 1999 to
225 2004, the National Health and Nutrition Examination Survey, reported that serum
226 total bilirubin levels were inversely associated with stroke outcomes.²³ Especially in
227 the Korean population, serum bilirubin concentration was estimated to be negatively
228 correlated with ischemic stroke in men.⁶
229 Additionally, several experimental studies support the results of this study. When
230 bilirubin acts as a ROS scavenger, indirect bilirubin (albumin-bound unconjugated
231 bilirubin) is oxidized to its non-toxic metabolic precursor biliverdin, which is then
232 recycled back to bilirubin by biliverdin reductase.^{19,24,25} In vitro studies have shown
233 that indirect bilirubin (unconjugated bilirubin bound to albumin) is oxidized by O_2^- ,
234 OH and HO_2 and that unconjugated bilirubin protects albumin from oxidation by O_2^- ,
235 OH , HO_2 and $ONOO^-$. Indirect bilirubin can act as an antioxidant by directly
236 scavenging ROS.^{19,25,26} In addition, indirect bilirubin has been shown to inhibit the
237 activity of NADPH oxidase, a major source of ROS in the vascular system, in vitro
238 and in vivo, suggesting that the production of ROS is reduced by indirect
239 bilirubin.^{18,27} Moreover, bilirubin has been shown to interact with other antioxidants to
240 synergistically inhibit lipid peroxidation.^{28,29} Taken together, these experimental
241 findings indicate that indirect bilirubin can function as an antioxidant by interacting

242 synergistically with other antioxidants to scavenge ROS, inhibit NADPH oxidase
243 activity, and inhibit lipid oxidation.

244 Bilirubin is a key indicator that continues to be studied today as studies have linked it
245 to the risk of oxidative stress-related diseases in humans, such as cardiovascular
246 disease, including stroke, diabetes, metabolic syndrome, certain cancers, and
247 autoimmune diseases.²⁹ The above research results suggest that specific studies of
248 other oxidative stress-related diseases can be conducted based on the detailed
249 bilirubin index and each bilirubin level presented by controlling various genetic
250 variables.

251 The strengths and limitations of this study are as follows. The strength is that
252 bilirubin data was obtained from KCPS-II and KoGES data as a Korean biobank for
253 two-sample MR analysis, and stroke data is large-scale data using the Japanese
254 biobank BBJ. Additionally, unlike previous studies, this is the first study to look at the
255 effects of direct and indirect bilirubin in addition to total bilirubin. A limitation is that
256 only ischemic stroke was included in the study, and total stroke and hemorrhagic
257 stroke were not included. However, in previous studies examining bilirubin and
258 stroke, only ischemic stroke showed a significant association.

259

260 **CONCLUSIONS**

261 This study causally proved that indirect bilirubin is a very significant causal protective
262 factor in the risk of ischemic stroke. However, when comparing systolic blood
263 pressure and indirect bilirubin, which are shown to be the same causal factor
264 although the direction is different, indirect bilirubin has a very wide confidence
265 interval. This implies that the reliability and statistical significance of the estimation

266 results remain low. In the future, it is believed that research should continue to gain a
267 deeper understanding of the protective effect of indirect bilirubin on ischemic stroke.

268 **Acknowledgements** We would like to thank the staff at Korea Medical Institute for
269 their assistance in data collection. We would also like to thank the staff at the other
270 11 general health examination centers who participated in this study for their
271 assistance in data collection.

272 **Source of Funding** This research was supported by a grant of the Korea Health
273 Technology R&D Project through the Korea Health Industry Development Institute
274 (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI20C0517).

275 **Disclosures**

276 None.

277 **Contributors** SHJ, KJJ and HK had full access to all of the data in the study and
278 takes responsibility for the integrity of the data and the accuracy of the data analysis.

279 Study concept and design: SHJ, KJJ and HK. Diagnostic testing and statistical
280 analysis: SHJ and KJJ.

281 Drafting of the manuscript: JWS and KJJ.

282 Critical revision of the manuscript for important intellectual content: SHJ and HK.

283 Study supervision and organization of the project: SHJ and HK.

284 **Ethical approval** This study protocol was approved by the Institutional Review
285 Board of the Severance Hospital (approval number: 4-2011-0277).

286

287 **ORCID iDs**

288 Jong Won Shin [http:// orcid. org/ 0009-0003-8587-1445](http://orcid.org/0009-0003-8587-1445)

289 Keum Ji Jung [http:// orcid. org/ 0000-0003-4993-0666](http://orcid.org/0000-0003-4993-0666)

290 Heejin Kimm [http:// orcid. org/ 0000 0003 4526 0570](http://orcid.org/0000000345260570)

291 Sun Ha Jee [http:// orcid. org/ 0000-0001-9519-3068](http://orcid.org/0000-0001-9519-3068)

292

293 **Figure legend**

294 Figure 1. Causal association between total, direct, and indirect bilirubin and ischemic

295 stroke using MVMR

296 **References**

297

298 1. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke.

299 Curr Hypertens Rep. 2011;13:200–207. doi: 10.1007/s11906-011-0195-x

300

301 2. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of

302 ischaemic stroke. Int J Stroke. 2009;4:461–470. doi: 10.1111/j.1747-

303 4949.2009.00387.x

304

305 3. Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic

306 mechanisms following ischemic stroke. Neurol Sci. 2017;38:1167–1186. doi:

307 10.1007/s10072-017-2938-1

308

309 4. Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating

310 total bilirubin and risk of incident cardiovascular disease in the general population.

311 Arterioscler Thromb Vasc Biol. 2015;35:716–724. doi:

312 10.1161/ATVBAHA.114.304929

313

314 5. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin

315 level, prevalent stroke, and stroke outcomes: nhanes 1999-2004. Am J Med.

316 2008;121:781–788 e781. doi: 10.1016/j.amjmed.2008.03.045

317

318 6. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent

319 predictor of stroke incidence: a prospective study in Korean men and women. Stroke.

320 2009;40:3422–3427. doi: 10.1161/STROKEAHA.109.560649

321

322 7. Oda E, Kawai R. A possible cross-sectional association of serum total bilirubin
323 with coronary heart disease and stroke in a Japanese health screening population.
324 Heart Vessels. 2012;27:29–36. doi: 10.1007/s00380-011-0123-7

325

326 8. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin
327 reductase antioxidant cycle. Pediatrics. 2004;113:1776–1782. doi:
328 10.1542/peds.113.6.1776

329

330 9. Gazzin S, Vitek L, Watchko J, Shapiro SM, Tiribelli C. A novel perspective on the
331 biology of bilirubin in health and disease. Trends Mol Med. 2016;22:758–768. doi:
332 10.1016/j.molmed.2016.07.004

333

334 10. Lee SJ, Jee YH, Jung KJ, Hong S, Shin ES, Jee SH. Bilirubin and Stroke Risk
335 Using a Mendelian Randomization Design. Stroke. 2017 May;48(5):1154-1160. doi:
336 10.1161/STROKEAHA.116.015083.

337

338 11. Choi Y, Lee SJ, Spiller W, Jung KJ, Lee JY, Kimm H, Back JH, Lee S, Jee SH.
339 Causal Associations Between Serum Bilirubin Levels and Decreased Stroke Risk: A
340 Two-Sample Mendelian Randomization Study. Arterioscler Thromb Vasc Biol. 2020
341 Feb;40(2):437-445. doi: 10.1161/ATVBAHA.119.313055.

342

343 12. Kim Y, Han B-G, KoGES group. Cohort Profile: The Korean Genome and
344 Epidemiology Study (KoGES) Consortium. Int J Epidemiol. 2017 Apr 1;46(2):e20. doi:
345 10.1093/ije/dyv316.

- 346 13. Jee YH, Emberson J, Jung KJ, Lee SJ, Lee S, Back JH, Hong S, Kimm H,
347 Sherliker P, Jee SH, Lewington S. Cohort Profile: The Korean Cancer Prevention
348 Study-II (KCPS-II) Biobank. *Int J Epidemiol.* 2018 Apr 1;47(2):385-386f. doi:
349 10.1093/ije/dyx226.
- 350 14. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T,
351 Tamakoshi A, Yamagata Z, Mushiroda T, et al. BioBank Japan Cooperative Hospital
352 Group; Kubo M. Overview of the BioBank Japan Project: Study design and profile.
353 *J Epidemiol.* 2017; 27(3S):S2-S8. doi: 10.1016/j.je.2016.12.005. Epub 2017 Feb 8.
354
- 355 15. O'Brien L, et al. Biliverdin reductase isozymes in metabolism. *Trends Endocrinol*
356 *Metab.* 2015;26(4):212–20. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
357
- 358 16. Tomaro ML, Batlle AM. Bilirubin: its role in cytoprotection against oxidative
359 stress. *Int J Biochem Cell Biol.* 2002;34(3):216–20. [[PubMed](#)] [[Google Scholar](#)]
360
- 361 17. Sundararaghavan VL, Sindhwani P, Hinds TD., Jr Glucuronidation and UGT
362 isozymes in bladder: new targets for the treatment of uroepithelial
363 carcinomas? *Oncotarget.* 2016 [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
364
- 365 18. Kwak JY, Takeshige K, Cheung BS, Minakami S: Bilirubin inhibits the activation
366 of superoxide-producing NADPH oxidase in a neutrophil cell-free system. *Biochimica*
367 *et biophysica acta*, 1991; 1076: 369-373 [[PubMed](#)] [[Google Scholar](#)]
368
- 369 19. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an
370 antioxidant of possible physiological importance. *Science*, 1987; 235; 1043-1046

371 [\[PubMed\]](#) [\[Google Scholar\]](#)

372 20. Li Y, Meng SY, Meng CC, Yu WG, Wang RT. Decreased serum bilirubin is
373 associated with arterial stiffness in men. *Nutr Metab Cardiovasc Dis.* 2013;23:375–
374 381. doi: 10.1016/j.numecd.2011.09.004

375

376 21. Mahabadi AA, Lehmann N, Möhlenkamp S, Kälsch H, Bauer M, Schulz R,
377 Moebus S, Jöckel KH, Erbel R, Heusch G. Association of bilirubin with coronary
378 artery calcification and cardiovascular events in the general population without
379 known liver disease: the Heinz Nixdorf Recall study. *Clin Res Cardiol.*
380 2014;103:647–653. doi: 10.1007/s00392-014-0697-z

381

382 22. Li RY, Cao ZG, Zhang JR, Li Y, Wang RT. Decreased serum bilirubin is
383 associated with silent cerebral infarction. *Arterioscler Thromb Vasc Biol.*
384 2014;34:946–951. doi: 10.1161/ATVBAHA.113.3030038

385 23. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total
386 bilirubin level, prevalent stroke, and stroke outcomes: nhanes 1999-2004. *Am J Med.*
387 2008;121:781–788 e781. doi: 10.1016/j.amjmed.2008.03.045

388

389 24. Baranano DE, Rao M, Ferris CD, Snyder SH: Biliverdin reductase: a major
390 physiologic cytoprotectant. *Proceedings of the National Academy of Sciences of the*
391 *United States of America*, 2002; 99: 16093-16098 [\[PMC free](#)

392 [article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)

393

394 25. Neuzil J, Stocker R: Bilirubin attenuates radical-mediated damage to serum
395 albumin. *FEBS letters*, 1993; 331: 281-284 [\[PubMed\]](#) [\[Google Scholar\]](#)

396

397 26. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D: Bilirubin is an effective

398 antioxidant of peroxynitrite-mediated protein oxidation in human blood

399 plasma. *Archives of biochemistry and biophysics*, 1998; 352: 165-174

400 [\[PubMed\]](#) [\[Google Scholar\]](#)

401

402 27. Lanone S, Bloc S, Foresti R, Almolki A, Taille C, Callebert J, Conti M, Goven D,

403 Aubier M, Dureuil B, El-Benna J, Motterlini R, Boczkowski J: Bilirubin decreases

404 nos2 expression via inhibition of NAD(P)H oxidase: implications for protection

405 against endotoxic shock in rats. *FASEB journal: official publication of the Federation*

406 *of American Societies for Experimental Biology*, 2005; 19: 1890-1892

407 [\[PubMed\]](#) [\[Google Scholar\]](#)

408

409 28. Stocker R, Peterhans E: Synergistic interaction between vitamin E and the bile

410 pigments bilirubin and biliverdin. *Biochimica et biophysica acta*, 1989; 1002: 238-244

411 [\[PubMed\]](#) [\[Google Scholar\]](#)

412

413 29. Neuzil J, Stocker R: Free and albumin-bound bilirubin are efficient co-

414 antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid

415 peroxidation. *The Journal of biological chemistry*, 1994; 269: 16712-16719

416 [\[PubMed\]](#) [\[Google Scholar\]](#)

417

418

419 Table 1. Causal effect of total bilirubin on ischemic stroke

	KoGES (total bilirubin), BBJ (ischemic stroke)		KCPS-II (total bilirubin), BBJ (ischemic stroke)	
	IVW method, OR (95% CI)	P	IVW method, OR (95% CI)	P
Crude two sample MR	0.86 (0.75-0.98)	0.0294	0.87 (0.77-0.99)	0.0652
MVMR				
Adjusted for LDL	0.86 (0.76-0.96)	0.0097	0.89 (0.79-1.01)	0.0669
Adjusted for HDL	0.82 (0.73-0.93)	0.0020	0.88 (0.79-0.99)	0.0326
Adjusted for TG*	0.99 (0.99-1.00)	0.0545	0.87 (0.78-0.98)	0.0174
Adjusted for LDL and HDL	0.96 (0.75-1.23)	0.7520	0.95 (0.81-1.12)	0.5259
Adjusted for LDL and TG	0.97 (0.76-1.23)	0.7910	0.91 (0.79-1.05)	0.2009
Adjusted for HDL and TG	0.84 (0.65-1.08)	0.1751	0.94 (0.82-1.09)	0.4217
Adjusted for LDL, HDL and TG	0.99 (0.78-1.25)	0.9070	0.94 (0.82-1.08)	0.3682
Adjusted for LDL, HDL, TG and SBP	0.93 (0.76-1.15)	0.5138	0.95 (0.84-1.08)	0.4658
Adjusted for LDL, TG and SBP	0.87 (0.64-1.19)	0.3891	0.92 (0.81-1.05)	0.2435
Adjusted for LDL, TG, SBP and FSG	0.90 (0.68-1.20)	0.4877	0.92 (0.81-1.05)	0.2136
Adjusted for LDL, TG, and FSG	0.83 (0.65-1.05)	0.1249	0.91 (0.79-1.04)	0.1720

420 KoGES, Korean Genome Epidemiologic Study; KCPS-II, Korean Cancer Prevention Study-II; BBJ, Biobank of Japan; IVW, inverse variance weighted
 421 method; OR, odds ratio; CI, confidence interval; MVMR, multivariable mendelian randomization; LDL, low density lipoprotein; HDL, high density lipoprotein;
 422 TG, triglyceride; SBP, systolic blood pressure; FBS, fasting serum glucose

423 Table 2. Causal effect of direct bilirubin on ischemic stroke

	KoGES (direct bilirubin), BBJ (ischemic stroke)		KCPS-II (direct bilirubin), BBJ (ischemic stroke)	
	IVW method, OR (95% CI)	P	IVW method, OR (95% CI)	P
Crude two sample MR	0.67 (0.45-1.00)	0.0493	0.65 (0.43-0.97)	0.0335
MVMR				
Adjusted for LDL	0.94 (0.55-1.60)	0.8173	0.64 (0.46-0.89)	0.0093
Adjusted for HDL	0.90 (0.52-1.56)	0.7202	0.65 (0.47-0.91)	0.0125
Adjusted for TG*	0.80 (0.47-1.36)	0.4136	0.64 (0.46-0.88)	0.0064
Adjusted for LDL and HDL	0.81 (0.37-1.77)	0.5987	0.72 (0.43-1.19)	0.2034
Adjusted for LDL and TG	1.02 (0.46-2.25)	0.9557	0.91 (0.56-1.46)	0.6940
Adjusted for HDL and TG	1.34 (0.73-2.46)	0.3469	0.84 (0.47-1.52)	0.5728
Adjusted for LDL, HDL and TG	0.72 (0.41-1.27)	0.2619	0.92 (0.59-1.45)	0.7304
Adjusted for LDL, HDL, TG and SBP	0.88 (0.49-1.60)	0.6847	0.94 (0.61-1.44)	0.7082
Adjusted for LDL, TG and SBP	0.97 (0.53-1.80)	0.9346	0.88 (0.57-1.36)	0.5563
Adjusted for LDL, TG, SBP and FSG	1.63 (0.96-2.77)	0.0727	0.88 (0.58-1.34)	0.5521
Adjusted for LDL, TG, and FSG	1.41 (0.85-2.31)	0.1784	0.91 (0.58-1.44)	0.6992

424 KoGES, Korean Genome Epidemiologic Study; KCPS-II, Korean Cancer Prevention Study-II; BBJ, Biobank of Japan; IVW, inverse variance weighted
 425 method; OR, odds ratio; CI, confidence interval; MVMR, multivariable mendelian randomization; LDL, low density lipoprotein; HDL, high density lipoprotein;
 426 TG, triglyceride; SBP, systolic blood pressure; FBS, fasting serum glucose


427 Table 3. Causal effect of indirect bilirubin on ischemic stroke

	KoGES (direct bilirubin), BBJ (ischemic stroke)		KCPS-II (direct bilirubin), BBJ (ischemic stroke)	
	IVW method, OR (95% CI)	P	IVW method, OR (95% CI)	P
Crude two sample MR	0.81 (0.68-0.97)	0.0253	0.84 (0.70-1.01)	0.0598
MVMR				
Adjusted for LDL	0.81 (0.65-1.02)	0.0800	0.84 (0.72-0.98)	0.0288
Adjusted for HDL	0.88 (0.71-1.08)	0.2262	0.85 (0.72-1.00)	0.0487
Adjusted for TG*	0.85 (0.69-1.06)	0.1526	0.82 (0.70-0.96)	0.0149
Adjusted for LDL and HDL	0.94 (0.62-1.44)	0.7936	0.87 (0.68-1.11)	0.2604
Adjusted for LDL and TG	0.98 (0.69-1.39)	0.8989	0.74 (0.55-0.99)	0.0429
Adjusted for HDL and TG	0.99 (0.63-1.57)	0.9868	0.87 (0.65-1.16)	0.3455
Adjusted for LDL, HDL and TG	0.79 (0.58-1.06)	0.1192	0.74 (0.56-0.98)	0.0355
Adjusted for LDL, HDL, TG and SBP	0.95 (0.70-1.30)	0.7647	0.78 (0.60-1.01)	0.0657
Adjusted for LDL, TG and SBP	1.14 (0.73-1.78)	0.5718	0.77 (0.59-0.99)	0.0505
Adjusted for LDL, TG, SBP and FSG	0.99 (0.99-1.00)	0.4297	0.76 (0.59-0.98)	0.0386
Adjusted for LDL, TG, and FSG	0.93 (0.60-1.42)	0.7384	0.75 (0.57-0.98)	0.0348

428 KoGES, Korean Genome Epidemiologic Study; KCPS-II, Korean Cancer Prevention Study-II; BBJ, Biobank of Japan; IVW, inverse variance weighted
 429 method; OR, odds ratio; CI, confidence interval; MVMR, multivariable mendelian randomization; LDL, low density lipoprotein; HDL, high density lipoprotein;
 430 TG, triglyceride; SBP, systolic blood pressure; FBS, fasting serum glucose


Figure 1

A




Total bilirubin and ischemic stroke

B



Direct bilirubin and ischemic stroke

C



Indirect bilirubin and ischemic stroke